Loading…
← CockpitCompetitor Analysis › 1779.HK LongBio Pharma (Suzhou) Co., Ltd. Class HOpen in the cockpit ↗

LongBio Pharma (Suzhou) Co., Ltd. Class H1779.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology

Suzhou-based Chinese biopharmaceutical company, per its industry classification; specific pipeline not independently confirmed.

Mkt cap
$510M
US dollars, full cap
Free float
21%
of shares outstanding
$/day
$1.36M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 5.6%
Hurdle
n/a
no reverse DCF
Close · HKDHK$51.35
1D+2.1%
1W-17.2%
1M-30.4%
3M-51.2%
6Mn/a
YTDn/a
1Yn/a
ATR %17.3%
52w lowhigh69.0% off high

What LongBio Pharma (Suzhou) does

Suzhou-based Chinese biopharmaceutical company, per its industry classification; specific pipeline not independently confirmed.

Where it sits in the supply chain

  • Biopharmaceuticals
  • Drug discovery & development

Moat: none

Headquarters: Suzhou, China · Employees: 85

LongBio Pharma (Suzhou) at a glance

Size LongBio Pharma (Suzhou) (1779.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $510M, the 741st largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$51.35 on 18 Nov 2026.

LongBio Pharma (Suzhou) financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
RevenueHK$0HK$0HK$0HK$0
Revenue growth————
Gross profit-HK$8.86M-HK$8.83M-HK$7.86M-HK$6.20M
EBITDA-HK$234M-HK$167M-HK$111M-HK$83.8M
Net income-HK$243M-HK$190M-HK$149M-HK$106M
Free cash flown/a-HK$137M-HK$118M-HK$70.0M
Capital expendituren/aHK$4.76MHK$6.66MHK$2.73M
Total debtn/aHK$42.2MHK$476MHK$347M

Quarterly statements and history in the cockpit →

LongBio Pharma (Suzhou) competitors and peer comparison

How LongBio Pharma (Suzhou) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

LongBio Pharma (Suzhou) against its 20 peers (data as of 18 Nov 2026)
Measure1779.HKPeer medianRank in peer set
1-month return-30.4%-9.5%2nd lowest of 21
Distance from 52-week high-69.0%-45.2%3rd lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
LongBio Pharma (Suzhou) 1779.HKHong Kong$510Mn/an/an/an/an/an/a
Valneva VLA.PAFrance$508M-6%-27%-87%3.9×n/an/a
Beijing Bohui Innovation Biotechnology 300318.SZChina$518M-20%-1%-13%6.2×n/an/a
Beijing Scitop Bio-Tech 300858.SZChina$501M-28%+4%8%7.5×n/an/a
Sinotherapeutics 688247.SSChina$494M-19%-17%0%6.2×29.4%+7.0%
Liaoning Dingjide Petrochemical 603255.SSChina$490M-24%+70%5%5.2×n/an/a
CHO Pharma 6586.TWOTaiwan$488M+24%-47%-17,694%8,281.1×n/an/a
Crescent Biopharma CBIOUnited States$482M-34%n/a-1,217%13.3×n/an/a
Frontage 1521.HKHong Kong$542M+113%+10%8%2.3×14.3%+15.4%
TaiMed Biologics 4147.TWOTaiwan$480M+19%+7%-31%22.7×n/an/a
Monopar Therapeutics MNPRUnited States$479M+9%n/an/an/an/an/a
Neurogene NGNEUnited States$479M-14%-100%n/an/an/an/a
Climb Bio CLYMUnited States$546M-12%n/an/an/an/an/a
Wave Life Sciences WVEUnited States$546M-55%-35%-321%2.2×n/an/a
Fennec Pharmaceuticals FENCUnited States$471M+37%+71%5%6.4×58.8%+204.7%
Hvsen Biotechnology 300871.SZChina$553M-22%+2%17%2.3×n/an/a
Sana Biotechnology SANAUnited States$554M-41%n/an/an/an/an/a
TenNor Therapeutics Suzhou 6872.HKHong Kong$470Mn/an/an/an/an/an/a
Kamada KMDAUnited States$465M+3%+5%15%2.0×5.0%+6.5%
Boji Medical Technology 300404.SZChina$561M-6%+32%4%3.4×31.9%+27.2%
DiaMedica Therapeutics DMACUnited States$463M+50%n/an/an/an/an/a

Questions

Which companies are LongBio Pharma (Suzhou)'s closest peers?
The cockpit's peer set: Valneva (VLA.PA), Beijing Bohui Innovation Biotechnology (300318.SZ), Beijing Scitop Bio-Tech (300858.SZ), Sinotherapeutics (688247.SS), Liaoning Dingjide Petrochemical (603255.SS), CHO Pharma (6586.TWO), Crescent Biopharma (CBIO), Frontage (1521.HK).

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.